No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
TRML241220C25000
- 2.00
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
2.00Open2.00Pre Close0 Volume2 Open Interest25.00Strike Price0.00Turnover0.00%IV30.75%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry2.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.33Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Leerink Partners Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Strategic Developments in Tourmaline Bio's Cardiovascular Programs Drive Buy Rating
Tourmaline Bio Unveils Clinical Progress and New Indication